Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)
Neuroprotection and Systemic Protection Studies: In rat models of traumatic brain injury, spinal cord injury, and peripheral nerve damage, the combination improved motor function recovery, reduced oxidative stress, preserved neuronal integrity, and counteracted secondary damage more effectively than individual administration
Itou Y, Nochi R, Kuribayashi H, Saito Y, Hisatsune T
Peptides don't replace standard care but augment it addressing aspects conventional treatments miss (neuroprotection beyond pressure lowering, enhanced antioxidant capacity beyond vitamins, tissue repair supporting medication effects)
Until clinical trials provide the necessary safety and efficacy data, conservative approaches grounded in existing evidence serve patients, clients, and the wellness community most effectively